Qualigen Therapeutics Inc
For the period ended Dec 31, 2023. Filed Apr 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 8, 2024
FFR$0.89-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| For the Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| EXPENSES | ||
| General and administrative | $6,095,607 | 10,274,600 |
| Research and development | 5,209,250 | 4,486,120 |
| Total expenses | 11,304,857 | 14,760,720 |
| LOSS FROM OPERATIONS | (11,304,857) | (14,760,720) |
| OTHER EXPENSE (INCOME), NET | ||
| Gain on change in fair value of warrant liabilities | (2,035,469) | (907,203) |
| Interest expense, net | 1,524,722 | 34,397 |
| Loss on voluntary conversion of convertible debt | 1,077,287 | — |
| Loss on debt extinguishment | 625,653 | — |
| Loss on fixed asset disposal | 21,747 | — |
| Other income, net | (38,994) | — |
| Total other expense (income), net | 1,174,946 | (872,806) |
| LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES | (12,479,803) | (13,887,914) |
| (BENEFIT) PROVISION FOR INCOME TAXES | (4,793) | 6,548 |
| NET LOSS FROM CONTINUING OPERATIONS | (12,475,010) | (13,894,462) |
| DISCONTINUED OPERATIONS | ||
| Loss from discontinued operations, net of tax | (683,008) | (7,140,181) |
| Loss on disposal of discontinued operations, net of tax | (602,232) | — |
| LOSS FROM DISCONTINUED OPERATIONS | (1,285,240) | (7,140,181) |
| NET LOSS | (13,760,250) | (21,034,643) |
| Net loss attributable to non-controlling interest from discontinued operations | (343,038) | (2,394,100) |
| Net loss attributable to Qualigen Therapeutics, Inc. | $(13,417,212) | $(18,640,543) |
| Net loss per common share, basic and diluted - continuing operations | $(2.46) | $(3.62) |
| Net loss per common share, basic and diluted - discontinued operations | $(0.19) | $(1.24) |
| Weighted-average number of shares outstanding, basic and diluted | 5,072,709 | 3,840,340 |
| Other comprehensive loss, net of tax | ||
| Net loss | $(13,760,250) | $(21,034,643) |
| Foreign currency translation adjustment from discontinued operations | 119,473 | 50,721 |
| Other comprehensive loss | (13,640,777) | (20,983,922) |
| Comprehensive loss attributable to noncontrolling interest from discontinued operations | (304,735) | (2,394,100) |
| Comprehensive loss attributable to Qualigen Therapeutics, Inc. | $(13,336,042) | $(18,589,822) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.